In our experiments, the feasibility of combination therapy comprised of in situ gene therapy with rAd-p53 and anti-PD-1 antibody was investigated in mouse syngeneic urogenital cancer models of kidney, bladder and prostate cancers. This evidence concerns the gene PDCD1 and urogenital neoplasm.